Increased odds seen for receiving neurodevelopmental diagnosis by 36 months, especially with third-trimester exposure, among male offspring<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Nov. 13, 2025 (HealthDay News) — Maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased risk for adverse neurodevelopmental diagnoses among offspring, according to a study published online Oct. 30 in Obstetrics & Gynecology<\/em>.<\/p>\n Lydia L. Shook, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a retrospective cohort study of live births to individuals who delivered between March 1, 2020, and May 31, 2021, to examine the impact of maternal SARS-CoV-2 infection on any neurodevelopmental diagnosis up to 36 months after birth. A total of 18,124 mother-child pairs were included in the analyses.<\/p>\n The researchers found that 140 offspring among 861 individuals with SARS-CoV-2-exposed pregnancies (16.3 percent) received a neurodevelopmental diagnosis by 36 months compared with 1,680 of 17,263 unexposed offspring (9.7 percent; unadjusted odds ratio, 1.80; adjusted odds ratio, 1.29). The largest effects were seen in third-trimester exposures overall and among male offspring (adjusted odds ratios, 1.36 and 1.43, respectively) in sensitivity analyses.<\/p>\n “These findings highlight that COVID-19, like many other infections in pregnancy, may pose risks not only to the mother, but to fetal brain development,” co-senior author Andrea G. Edlow, M.D., from Massachusetts General Hospital, said in a statement. “They also support the importance of trying to prevent COVID-19 infection in pregnancy and are particularly relevant when public trust in vaccines — including the COVID-19 vaccine — is being eroded.”<\/p>\n Two authors disclosed ties to the biopharmaceutical and medical device industries.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n